Sagent Pharmaceuticals

Sagent Pharmaceuticals is a healthcare company that specializes in the development and manufacturing of injectable pharmaceuticals. Known for producing essential medications, including injectable pentobarbital, the company has taken a public stance against the use of its products in capital punishment.

CCI Score

-4.89

0.01% April 18

Latest Event

Voluntary Recall of Docetaxel Injection

On May 28, 2024, Sagent Pharmaceuticals announced a voluntary nationwide recall of two lots of Docetaxel Injection, USP due to potential particulate contamination. This action, initiated after a customer complaint and with FDA oversight, underscores the company's commitment to consumer safety and ethical business practices.

Take Action

So what can you do? It's time to make tough choices. Where will you cast your vote?

Shop Alternatives SEE ALL: Hikma

GSK

Merck
Use Your Voice OTHER TOOLS
Investigate
Share the Score SUPPORT CCI

BYSTANDER

Sagent Pharmaceuticals is currently rated as a Bystander.

-1 to -4 CCI Score

Companies scoring here do little to oppose authoritarianism. Their inaction results in a passive endorsement of the status quo, as they neither actively resist oppression nor contribute to overt support for it.

Latest Events

MAY

28

2024

Voluntary Recall of Docetaxel Injection
54.88

On May 28, 2024, Sagent Pharmaceuticals announced a voluntary nationwide recall of two lots of Docetaxel Injection, USP due to potential particulate contamination. This action, initiated after a customer complaint and with FDA oversight, underscores the company's commitment to consumer safety and ethical business practices.
+60

Business Practices and Ethical Responsibility

April 4

The voluntary recall demonstrates proactive risk management and accountability in ensuring product safety. This move reflects responsible business practices by addressing potential safety risks before adverse events occur, thereby aligning the company with ethical standards that protect public welfare and counteract neglect that can enable authoritarian or harmful practices.

Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Docetaxel Injection, USP Due to Potential Presence of Particulate Matter
JAN

01

2024

Sagent Pharmaceuticals Warns Against Use of Its Drugs in Executions
50.00

Sagent Pharmaceuticals, known for producing injectable pentobarbital, sent warning letters to Idaho officials last year, stating that it reserves the right to take legal action if its products are diverted for capital punishment. This action reinforces the company’s public stance against the use of its drugs in executions.
DEC

31

2023

Sagent Pharmaceuticals Lobbying Expenditure 2023
-70.25

Sagent Pharmaceuticals, through its Sagent M&C profile, spent $980,000 on lobbying in 2023, as reported by OpenSecrets. This figure highlights the company’s active engagement in influencing political processes.
-80

Political Contributions and Lobbying Efforts

April 4

The company's significant lobbying expenditure of $980,000 in 2023 indicates a deliberate effort to shape political outcomes. From an anti-fascist perspective, such corporate lobbying raises concerns regarding the undue influence over democratic processes and policy-making, potentially undermining transparency and accountability.

Sagent M&C Lobbying Profile • OpenSecrets
DEC

31

2023

Sagent Pharmaceuticals Spends $980K on Lobbying in 2023
-26.34

OpenSecrets reported that Sagent M&C, associated with Sagent Pharmaceuticals, spent $980,000 on lobbying during 2023. The report details this expenditure as part of the firm's political influence activities.
-30

Political Contributions and Lobbying Efforts

April 4

The report indicates that Sagent M&C spent $980,000 lobbying in 2023. While the specific issues lobbied are not detailed, such a significant expenditure for political influence raises concerns over corporate engagement in shaping policy outcomes. This level of political spending is evaluated negatively from an anti-fascist perspective, as it can contribute to corporate undermining of democratic accountability.

Sagent M&C Issues Lobbied • OpenSecrets
APR

20

2023

Settlement for Pricing Data Non-Compliance
-32.75

On April 20, 2023, Sagent Pharmaceuticals entered into a $175,000 settlement with the OIG over allegations of failing to submit timely certified quarterly Average Sales Price data to CMS for multiple quarters between Q2 2020 and Q3 2022.
-40

Business Practices and Ethical Responsibility

April 4

Sagent Pharmaceuticals' failure to submit the required pricing data demonstrates a lapse in ethical business practices and regulatory compliance. This non-cooperative behavior undermines transparency and accountability, negatively reflecting on its overall business ethics.

Sagent Pharmaceuticals Agreed to Pay $175,000 for Allegedly Violating the Civil Monetary Penalties Law by Failing to Submit Timely Pricing Data